ASGCT – Novartis, Juno & UltraHuman to discuss off-target screening


If you are attending ASGCT later this month then please join us for a symposium featuring guest speakers from Novartis, Juno and UltraHuman Limited:

Off-target screening of biotherapeutics and cell therapies

Tuesday April 30, 12:00 – 1:30pm
Chair: Jim Freeth, PhD, Retrogenix Limited

‘Understanding and predicting CAR T cell off-target activity’
 – Thomas Long, PhD, Senior Scientist, Juno Therapeutics, a Celgene Company

‘Monoclonality does not equal monospecificity – polyspecificity is a critical development risk for antibody-based therapeutics’
 – William Finlay, PhD, CEO, UltraHuman Limited

‘Early cross reactivity screening of various biologic modalities’
 – Tim MacLachlan PhD, Executive Director, Preclinical Safety, Novartis

ASGCT runs from 29th April – to 2nd May 2019 in Washington DC. If you are not attending the conference but would like to start a discussion then please do get in touch.